Glioblastoma in England: 2007–2011

Brodbelt, Andrew; Greenberg, David; Winters, Tim; Williams, Matthew; Vernon, Sally; Collins, V. Peter

doi:10.1016/j.ejca.2014.12.014

Cited by 192 publications

(164 citation statements)

References 22 publications

Supporting

Mentioning

150

Contrasting

Unclassified

Order By: Relevance

“…GBM represents the most common and most lethal type of primary malignant brain tumor in adults with an age-adjusted incidence rate of 3.2 to 4.5 per 100,000 (46,47). Median survival (treated by current standard of care -maximal resection and radiotherapy with concomitant and adjuvant temozolomide) is 16-17 months (48), and only 9.8% of patients are still alive at five years (49).…”

Section: Clinical Trials Of Ttfields In Gbmmentioning

confidence: 99%

Tumor-Treating Fields: A Fourth Modality in Cancer Treatment

Mun

Babiker

Weinberg³

et al. 2018

Clinical Cancer Research

288

181

View full text Add to dashboard Cite

Despite major advances in therapy, cancer continues to be a leading cause of mortality. In addition, toxicities of traditional therapies pose a significant challenge to tolerability and adherence. TTFields, a noninvasive anticancer treatment modality, utilizes alternating electric fields at specific frequencies and intensities to selectively disrupt mitosis in cancerous cells. TTFields target proteins crucial to the cell cycle, leading to mitotic arrest and apoptosis. TTFields also facilitate an antitumor immune response. Clinical trials of TTFields have proven safe and efficacious in patients with glioblastoma multiforme (GBM), and are FDA approved for use in newly diagnosed and recurrent GBM. Trials in other localized solid tumors are ongoing. Clin Cancer Res; 24(2); 266-75. Ó2017 AACR.

show abstract

Section: Clinical Trials Of Ttfields In Gbmmentioning

confidence: 99%

Tumor-Treating Fields: A Fourth Modality in Cancer Treatment

Mun

Babiker

Weinberg³

et al. 2018

Clinical Cancer Research

288

181

View full text Add to dashboard Cite

show abstract

“…However, recurrences result from the resistances to chemotherapy and radiation has been the great challenges of glioma patients. 2,14) To overcome these limitations, novel chemotherapies or combination treatments are drawing great gravitation to preclinical and clinical research. Enediyne antibiotics, a group of DNAcleaving natural product, have been proposed for treatment of various human cancers, especially NCS, has been an effective and novel chemotherapeutic agent to nervous system cancer, 43) therefore, our study was designed to test the combinational effects of NCS plus PTX.…”

Section: Discussionmentioning

confidence: 99%

“…The 5-years survival of glioblastoma patients are only 5%, and the median survival times of glioblastoma patients are 12-15 months. 1,2) At present, the common clinic treatments of glioblastoma are surgery concomitant with radiotherapy or chemotherapy. But it is very difficult to control the progress of glioblastoma, the recurrence after first therapy is rapid for most of patients, meanwhile, the poor prognosis and survival outcome are also partially associated with races and ages, in which although the morbidity and the mortality are significantly different, the overall survival rate is not dramatically improved.…”

mentioning

confidence: 99%

“…Although the malignance of glioma urgently promoted the developments of some attractive medicinal strategies, including targeting therapy, gene therapy and immunotherapy, the first-line strategies of glioma therapy are still mainly alkylating agents concomitant or after radiotherapy, [10][11][12][13] nevertheless, the consequential low sensitivities or intolerance to novel therapies and the multi-drugs resistance (MDR) to the chemotherapy have badly stroked the patients' expectation, which drove more efforts to pressingly pursue the effective and feasible clinic strategies. 2,14) Enediyne antibiotic is a group of natural agents produced by microbial metabolism with potential anti-tumoral effects. At present, enediyne antibiotics are the most potent in currently known anti-tumoral agents.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Synergistic Anti-glioma Effects in Vitro and in Vivo of Enediyne Antibiotic Neocarzinostatin and Paclitaxel via Enhanced Growth Delay and Apoptosis-Induction

Tianqin

Chen²,

Wang

2016

Biological & Pharmaceutical Bulletin

View full text Add to dashboard Cite

Neocarzinostatin (NCS) is a member of enediyne antibiotics with high anticancer potential. Our study was performed to explore the synergistic anti-glioma effects of NCS and paclitaxel (PTX) in vitro and in vivo. By 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, the cytotoxicities of the drugs to human glioma cells U87MG and rat glioma cells C6 were evaluated. The results showed that the combinations of NCS and PTX can synergistically inhibit glioma cells survival. Cell apoptosis was detected by flow cytometry, and the results showed that the combinations of NCS and PTX synergistically enhanced apoptosis ratio of glioma cells. Western blot revealed that the cell signaling pathways of proliferation and apoptosis were synergistically regulated, in which Akt was synergistically inactivated, p53 was up-regulated with down-regulation of bcl-2. Meanwhile, with the subcutaneous model of U87MG cells and intracerebral implantation model of C6 cells, the combination strategy could synergistically delay the glioma growth and significantly prolong the survival of rats bearing orthotopic glioma. This study demonstrates that the combination of NCS and PTX can potentiate the effect on survival and apoptosis of glioma cells via suppression of Akt, bcl-2, and activations of p53; Meanwhile, the in vivo studies also confirmed that the combination of NCS and PTX synergistically inhibit the gliom growth. Our data about the combinational effects of NCS with PTX may provide an alternative strategy for glioma therapy.

show abstract

“…Incidence peaks in the 7 th and 8 th decades of life and as our global population ages, rates are increasing. Outcomes from this disease remain poor with median life expectancy in England at 6.1 months, dropping to 3.2 months amongst those aged over 70 [1].…”

Section: Introductionmentioning

confidence: 99%

Glioblastoma in the elderly — How do we choose who to treat?

Lorimer¹,

Saran

Chalmers

et al. 2016

Journal of Geriatric Oncology

View full text Add to dashboard Cite

Glioblastoma (GBM) is the commonest primary malignant brain tumour among the adult population. Incidence peaks in the 7 th and 8 th decades of life and as our global population ages, rates are increasing. GBM is an almost universally fatal disease with life expectancy in the range of 3-5 months amongst the elderly.The assessment of elderly GBM patients prior to treatment decisions is poorly researched and unstandardized. In order to begin tackling this issue we performed a cross-sectional survey across all UK based consultant neuro oncologists to review their current practice in assessing elderly GBM patients.There were 56 respondents from a total of 93 recipients (60% response rate). All respondents confirmed that at least some patients aged 70 or over were referred to their clinics from the local multidisciplinary team meeting (MDT). Only 18% of consultants routinely performed a cognitive or frailty screening test at initial consultation. Of those who performed a screening test, the majority reported that the results of the test changed their treatment decision in approximately 50% of cases. Participants ranked performance status as the most important factor in determining treatment decisions.Considering the heterogeneity of this patient population, we argue that performance status is a crude measure of vulnerability within this cohort. Elderly GBM patients represent a unique clinical scenario because of the complexity of distinguishing neuro oncology related symptoms from general frailty. There is a need for specific geriatric assessment models tailored to the elderly neuro oncology population in order to facilitate treatment decisions.

show abstract

Glioblastoma in England: 2007–2011

Abstract: The overall outcome for patients with GBM remains poor. However, aggressive treatment at every age group is associated with extended survival similar to that described in clinical trials.

Cited by 192 publications

References 22 publications

Tumor-Treating Fields: A Fourth Modality in Cancer Treatment

Tumor-Treating Fields: A Fourth Modality in Cancer Treatment

Synergistic Anti-glioma Effects <i>in Vitro</i> and <i>in Vivo</i> of Enediyne Antibiotic Neocarzinostatin and Paclitaxel <i>via</i> Enhanced Growth Delay and Apoptosis-Induction

Glioblastoma in the elderly — How do we choose who to treat?

Contact Info

Product

Resources

About